Hepatitis C, A global issue: Access to care and new therapeutic and preventive approaches in resource-constrained areas

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 89-97

  Lemoine, Maud ^a   Thursz, Mark ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

access to treatment; chronic hepatitis C; direct acting antivirals; hepatitis C virus; prevalence; resource limited countries

Indexed keywords

ANTIMONY TARTRATE; BOCEPREVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL THERAPY; ARTICLE; ASIA; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG COST; EASTERN EUROPE; HEALTH CARE ACCESS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEASUREMENT ACCURACY; MEDICAL EDUCATION; MIDDLE EAST; MIXED INFECTION; NORTH AFRICA; PRACTICE GUIDELINE; PREVALENCE; PREVENTION; PRIORITY JOURNAL; RESOURCE LIMITED COUNTRY; RESOURCE MANAGEMENT; SCREENING; SKILL; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW (TOPIC); VOCATIONAL EDUCATION; DEVELOPING COUNTRY; ECONOMICS; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEPATITIS C, CHRONIC; LEGISLATION AND JURISPRUDENCE; SUPPLY AND DISTRIBUTION; TRANSMISSION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG COSTS; GLOBAL HEALTH; HEALTH POLICY; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HEPATITIS C, CHRONIC; HUMANS; PREVALENCE; TREATMENT OUTCOME;

EID: 84899654821     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371082     Document Type: Article

References (64)

1. Mohd Hanafiah K., Groeger J., Flaxman A. D., Wiersma S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology: 2013; 57 4 1333 1342
2. Wantuck J. M., Ahmed A., Nguyen M. H. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther: 2014; 39 2 137 147
3. Thursz M., Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol: 2014; 11 1 28 35
4. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet: 2012; 380 9859 2095 2128
5. Lemoine M., Thursz M., Njie R., Dusheiko G. Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver Int: 2014; 34 1 12 15
6. Cooke G. S., Lemoine M., Thursz M., et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat: 2013; 20 9 600 601
7. Sievert W., Altraif I., Razavi H. A., et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int: 2011; 31 02 61 80
8. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat: 1999; 6 1 35 47
9. Shepard C. W., Finelli L., Alter M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis: 2005; 5 9 558 567 (Pubitemid 41196755)
10. Nguyen L. H., Nguyen M. H. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther: 2013; 37 10 921 936
11. Pham D. A., Leuangwutiwong P., Jittmittraphap A., et al. High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol: 2009; 27 2-3 153 160
12. Thu Thuy P. T., Bunchorntavakul C., Tan Dat H., Rajender Reddy K. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol: 2012; 56 5 1012 1018
13. Guerra J., Garenne M., Mohamed M. K., Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat: 2012; 19 8 560 567
14. Frank C., Mohamed M. K., Strickland G. T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet: 2000; 355 9207 887 891 (Pubitemid 30137669)
15. Lehman E. M., Wilson M. L. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J Viral Hepat: 2009; 16 9 650 658
16. Hope V. D., Eramova I., Capurro D., Donoghoe M. C. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect: 2014; 142 2 270 286
17. Hatzakis A., Van Damme P., Alcorn K., et al. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat: 2013; 20 02 1 20
18. Payan C., Roudot-Thoraval F., Marcellin P., et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat: 2005; 12 4 405 413 (Pubitemid 40961481)
19. Ansaldi F., Bruzzone B., Salmaso S., et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol: 2005; 76 3 327 332 (Pubitemid 40770887)
20. Katsoulidou A., Sypsa V., Tassopoulos N. C., et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat: 2006; 13 1 19 27
21. Medrano J., Resino S., Vispo E., et al. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat: 2011; 18 5 325 330
22. Kershenobich D., Razavi H. A., Sánchez-Avila J. F., et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int: 2011; 31 02 18 29
23. Karoney M. J., Siika A. M. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J: 2013; 14 44
24. Madhava V., Burgess C., Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis: 2002; 2 5 293 302 (Pubitemid 34464740)
25. Markov P. V., Pepin J., Frost E., Deslandes S., Labbé A. C., Pybus O. G. Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J Gen Virol: 2009; 90 Pt 9 2086 2096
26. Njouom R., Caron M., Besson G., et al. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS ONE: 2012; 7 8 e42002
27. Njouom R., Frost E., Deslandes S., et al. Predominance of hepatitis C virus genotype 4 infection and rapid transmission between 1935 and 1965 in the Central African Republic. J Gen Virol: 2009; 90 Pt 10 2452 2456
28. Antaki N., Abboud D., Antaki F., Craxi A. HCV genotype 5: an orphan virus. Antivir Ther: 2013; 18 3 263 269
29. Xia Y. H., Chen W., Tucker J. D., Wang C., Ling L. HIV and hepatitis C virus test uptake at methadone clinics in Southern China: opportunities for expanding detection of bloodborne infections. BMC Public Health: 2013; 13 899
30. Quan V. M., Go V. F., Nam V., et al. Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care: 2009; 21 1 7 16
31. Nelson P. K., Mathers B. M., Cowie B., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet: 2011; 378 9791 571 583
32. Rockstroh J. K., Mocroft A., Soriano V., et al. EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis: 2005; 192 6 992 1002 (Pubitemid 41266795)
33. Barth R. E., Huijgen Q., Taljaard J., Hoepelman A. I. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis: 2010; 14 12 e1024 e1031
34. Ladep N. G., Agaba P. A., Agbaji O., et al. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol: 2013; 19 10 1602 1610
35. Laurent C., Bourgeois A., Mpoudi-Ngolé E., et al. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med: 2010; 11 1 85 89
36. Bowring A. L., Luhmann N., Pont S., et al. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. Int J Drug Policy: 2013; 24 1 78 81
37. Raguin G., Lepretre A., Ba I., et al. Drug use and HIV in West Africa: a neglected epidemic. Trop Med Int Health: 2011; 16 9 1131 1133
38. Joshi D., O'Grady J., Dieterich D., Gazzard B., Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet: 2011; 377 9772 1198 1209
39. Salmon-Ceron D., Rosenthal E., Lewden C., et al. ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol: 2009; 50 4 736 745
40. Dodd R. Y., Notari E. P. IV, Stramer S. L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion: 2002; 42 8 975 979
41. Hauri A. M., Armstrong G. L., Hutin Y. J. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS: 2004; 15 1 7 16 (Pubitemid 38096122)
42. Pépin J., Lavoie M., Pybus O. G., et al. Risk factors for hepatitis C virus transmission in colonial Cameroon. Clin Infect Dis: 2010; 51 7 768 776
43. Kandeel A. M., Talaat M., Afifi S. A., et al. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. BMC Infect Dis: 2012; 12 294
44. Chlabicz S., Grzeszczuk A., Prokopowicz D. Medical procedures and the risk of iatrogenic hepatitis C infection: case-controlled study in north-eastern Poland. J Hosp Infect: 2004; 58 3 204 209 (Pubitemid 39462588)
45. Safi S. Z., Waheed Y., Sadat J., et al. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Trop Biomed: 2012; 2 7 532 536
46. Lemoine M., Nayagam S., Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol: 2013; 8 4 371 380
47. World Hepatitis Alliance Available at: http://www.who.int/immunization/ topics/hepatitis-b-survey-2010/en/. Accessed January 5, 2014
48. Hatzakis A., Wait S., Bruix J., et al. The state of hepatitis B and C in Europe: report from the Hepatitis B and C Summit Conference. J Viral Hepat: 2011; 18 01 1 16
49. Thomas D. L. Curing hepatitis C with pills: a step toward global control. Lancet: 2010; 376 9751 1441 1442
50. World Health Organization Available at: http://www.who.int/csr/disease/ hepatitis/global-report/en/index.html. Accessed January 7, 2014
51. Centers for Disease Control and Prevention (CDC) Progress toward prevention and control of hepatitis C virus infection-Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep: 2012; 61 29 545 549
52. Eurasian harm reduction network (EHRN) 2013. Available at: http://www.idhdp.com/media/33100/ehrn-hepatitis-c-treatment-access-in-eeca.pdf. Accessed January 5, 2014
53. Marseille E., Hofmann P. B., Kahn J. G. HIV prevention before HAART in sub-Saharan Africa. Lancet: 2002; 359 9320 1851 1856 (Pubitemid 34607065)
54. UNAIDS Guidelines for 2014 Global AIDS response progress reporting. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf. Accessed January 6, 2014
55. WTO The Doha declaration explained. Available at: http://www.wto.org/ english/thewto-e/minist-e/min01-e/mindecl-trips-e.pdf. Accessed January 6, 2014
56. Hill A. Minimum costs to provide hepatitis C direct acting antivirals. Available at: http://freepdfhosting.com/d4a7e2bba6.pdf. Accessed January 7, 2014
57. Medicines Patent Pool. Advancing innovation, access, and public health. Available at: http://www.medicinespatentpool.org. Accessed January 7, 2014
58. Ford N., Singh K., Cooke G. S., et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis: 2012; 54 10 1465 1472
59. Bouvier-Alias M., Patel K., Dahari H., et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology: 2002; 36 1 211 218 (Pubitemid 34700780)
60. WHO Prevention and control of viral hepatitis infection: framework for global action. Available at: http://www.who.int/csr/disease/hepatitis/GHP- framework.pdf. Accessed January 6, 2014
61. Edlin B. R. Perspective: test and treat this silent killer. Nature: 2011; 474 7350 S18 S19
62. Hagan L. M., Wolpe P. R., Schinazi R. F. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol: 2013; 21 12 625 633
63. Hagan L. M., Schinazi R. F. Best strategies for global HCV eradication. Liver Int: 2013; 33 01 68 79
64. Thomas D. L. Global control of hepatitis C: where challenge meets opportunity. Nat Med: 2013; 19 7 850 858